SOP 407: PROTOCOL DEVIATIONS AND UNANTICIPATED PROBLEMS

Similar documents
Reporting an Unanticipated Problem Involving Risks to Subjects or Others (UPIRTSO) to the IRB

UNIVERSITY OF TENNESSEE GRADUATE SCHOOL OF MEDICINE INSTITUTIONAL REVIEW BOARD CONTINUING REVIEW AND REAPPROVAL OF RESEARCH

Michigan State University Human Research Protection Program

Yale University Human Research Protection Program

University of Pennsylvania Institutional Review Board. Reliance Agreement Guidance: Post-Approval Submissions

SOP 801: Investigator Qualifications and Responsibilities

Supersedes Document Dated: 7/7/11. SOP: RR 401 Version No.: 07 Version Date: 9/8/15 EXPEDITED REVIEW 1. POLICY

SUSPENSION OR TERMINATION OF HUMAN SUBJECTS RESEARCH

Wayne State University Institutional Review Board

Institutional Review Board Standard Operating Procedure. Suspension and Termination of IRB Approval

NONCOMPLIANCE. 1. Overview

CONTINUING REVIEW CRITERIA FOR RENEWAL

Issue in IRB Approvals:

CONTINUING REVIEW CRITERIA FOR RENEWAL

UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER INSTITUTIONAL REVIEW BOARD CONTINUING REVIEW OF RESEARCH

IOWA STATE UNIVERSITY Institutional Review Board. Policy on IRB Review of Protocol Deviations and Noncompliance for Non-exempt Research

the HRPP Director will prepare a draft report within three (3) workdays after the IRB meeting at which the determination occurred.

Administrative Hold, Suspension, or Termination of IRB Approval

Human Research Protection Program Policy

SYRACUSE UNIVERSITY HUMAN RESEARCH PROTECTION PROGRAM STANDARD OPERATING PROCEDURES

EXPEDITED REVIEW. Terms used in this policy, but not defined herein shall have the meanings set forth in the Glossary.

CONTINUING REVIEW 3/7/2016

To assure knowledge and compliance by documenting the annual administrative review and continuing IRB review of non-exempt projects for the IRB.

Children s Hospital of Philadelphia Committees for the Protection of Human Subjects Policies and Procedures Continuing Review of Approved Research

AMENDMENTS TO PREVIOUSLY APPROVED RESEARCH 3/01/2016

University of Iowa External/Central IRB Reliance Process Standard Operating Procedure (SOP)

To assure knowledge and compliance by documenting the continuing review procedure of approved projects for the IRB.

OHRP Guidance on Written IRB Procedures

COMPLIANCE MONITORING

Tuesday, May 15, Please be sure to sign in and take copies of each handout.

Signature Date Date First Effective: Signature Date Revision Date:

UNIVERSITY OF TENNESSEE GRADUATE SCHOOL OF MEDICINE INSTITUTIONAL REVIEW BOARD PROCEDURES FOR FULL BOARD REVIEW

Independent Ethics Committees

Human Subjects in Research Review and Monitoring Form. Not applicable

UNIVERSITY OF GEORGIA Institutional Review Board

CONTINUING REVIEW OF APPROVED IRB PROTOCOLS

Guidance for IRBs, Clinical Investigators, and Sponsors IRB Continuing Review after Clinical Investigation Approval

IRB MEETING ADMINISTRATION

SOP #2-2 Version #1 Date First Effective: December 14, Page 1 of 6

HSPP Standard Operating Procedures

Standard Operating Policy and Procedures (SOPP) 3:

SOP 903: HRPP AND NON-COMPLIANCE

INSTITUTIONAL REVIEW BOARD (IRB) PROCEDURES

CUNY HRPP Policy: Suspension or Termination of Human Subject Research

POLICY NO EXEMPT RESEARCH... 4 POLICY NO DISCLOSURE OF RESEARCH LAB TEST RESULTS... 5

Lapse in IRB Approval

Study Management SM STANDARD OPERATING PROCEDURE FOR Interactions with the Institutional Review Board (IRB)

Section 8. Continuing Review of Ongoing IRB-Approved Research (Revised 7/1/10)

IRB Chair Responsibilities

7.0 DEVIATION and EXCEPTION of a PREVIOUSLY APPROVED PROTOCOL

Florida State University IRB Standard Operational Procedures

Baptist Health Institutional Review Board. Study Closure Report (Expedited Review) IRB #: Study Title:

The Children s Hospital of Philadelphia Committee for the Protection of Human Subjects Policies and Procedures. Cooperative Agreements

Chapter 4 Institutional Review Board (IRB) Roles and Authorities

Cayuse IRB Policy and Procedure Manual

Initial Review. Approved By: Michele Kennett, JD, MSN, LLM Associate Vice Chancellor for Research. Table of Contents

EMERGENCY USE 03/02/2016

Procedure Department: HUMAN RESEARCH PROTECTIONS PROGRAM Policy Number: II.B.1

Children s Hospital of Philadelphia Committees for the Protection of Human Subjects Policies and Procedures. IRB Review Processes

Yale University Institutional Review Boards

HEALTH CARE SYSTEMS RESEARCH NETWORK

Review of Research by the Convened IRB

I. Summary. II. Responsibilities

Date Effective 4/21/2008 Identification

University of Pennsylvania Institutional Review Board. Reliance Agreement Guidance: Penn as Central IRB FAQ

Illinois Institute of Technology Institutional Review Board Handbook of Procedures for the Protection of Human Research Subjects

Effective Date Revisions Date Review by the Convened Institutional Review Board

Research Involving Human Subjects: AA 110.7

Human Research Protections Program Medical College of Wisconsin and Froedtert Memorial Lutheran Hospital

Investigator Manual. If you have questions about whether an activity requires IRB review, contact the IRB Office.

SYRACUSE UNIVERSITY HUMAN RESEARCH PROTECTION PROGRAM STANDARD OPERATING PROCEDURES 02 06/30/10 08/01/07 1 OF 6

Version 1. Submission Guide and Policies

Oklahoma State University Institutional Review Board Standard Operating Procedures

University of Wisconsin Colleges Administrative Policy #56 NON-COMPLIANCE IN HUMAN SUBJECTS RESEARCH

Harvard University Area IRB Standard Operating Procedures

INSTITUTIONAL REVIEW BOARD (IRB) PROCEDURES

IRB Minutes Quality Improvement Assessment

Signature Date Date First Effective: Signature Date Revision Date: 07/18/2011

SOP 5.06 Full Committee Review: Initial IRB Review

IRB COMPOSITION AND IRB MEMBER ROLES AND RESPONSIBILITIES

RESEARCH PROTECTIONS OFFICE

21 CFR Part 56 - Institutional Review Boards

I. Summary. II. Responsibilities

Institutional Responsibilities Under A Federalwide Assurance

PRINCIPAL INVESTIGATOR S ACKNOWLEDGMENT OF RESPONSIBILITIES

2.0 Institutional Review Board

Ceded IRB Review. The project involves prisoners or other vulnerable populations that require special considerations.

SOP Title Review of Research: Devices for Humanitarian Uses

Effective Date: January 16, 2012 Policy Number: Appendix II. Revised Date: November 2, 2015 Oversight Level: Corporate

Institutional Review Board (IRB) Policies and Procedures Manual

IRB-REQUIRED INVESTIGATOR ACTIONS

IRB MEMBERSHIP COMPOSITION, ROLES AND RESPONSIBILIES

Collaborative Research

SMART IRB Agreement Implementation Checklist and Documentation Tool

Effective Date: January 16, 2012 Policy Number: MHC_RP0107. Revised Date: November 2, 2015 Oversight Level: Corporate

Title: EXPEDITED IRB REVIEW OF HUMAN SUBJECTS RESEARCH

RESEARCH SUBMISSION REQUIREMENTS

IRB Authorization Agreement Implementation Checklist and Documentation Tool

University of Cincinnati. Radiation Safety Committee Operations Guidelines Statement of Policy (RSC Guidelines) RSC Guidelines (revision 5)

Policy Number: 42 Title: Investigational Devices Date of Last Revision: 06/12/2008; 07/22/2010; 05/29/2013; 05/01/2016; 10/16/2018

Transcription:

University of Oklahoma Office of Human Research Participant Protection : PROTOCOL DEVIATIONS AND UNANTICIPATED PROBLEMS 1. POLICY Protocol deviations and unanticipated problems may be discovered in a variety of ways, including but not limited to discovery by research staff, IRB Staff or IRB Reviewers; Quality Improvement (QI)/Evaluation processes; communications with research participants; or communications from related University administrative units. Despite the method of discovery, investigators are required to promptly report to the IRB any event that may represent a major protocol deviation and/or unanticipated problem as described below. At the time of Continuing Review, Investigators shall report to the IRB minor protocol deviations and other harm caused to research participants that do not constitute an unanticipated problem. Specific Policies 1.1 PROTOCOL DEVIATIONS 1.1.1 Protocol Deviation: A protocol deviation is any change, divergence, or departure from the research study approved by the IRB. Upon discovery, the Principal Investigator is responsible for reporting major protocol deviations as described in Section 1.1.3 below to the IRB within five (5) days using the Protocol Deviation form available on the electronic information system. 1.1.2 Minor Protocol Deviation: A minor protocol deviation is any change, divergence, or departure from the research protocol that has not been approved by the IRB and that DOES NOT have a major impact on the participant's rights, safety, or well-being or on the completeness, accuracy, and reliability of the research project data. (Examples include, but are not limited to: study procedure or participant visit conducted out of time frame, or blood samples obtained at times close to but not at the time specified in the IRB approved protocol, or having participants sign a non-stamped consent document, not providing the participant with copies of the consent documents.) Changes or alterations in the conduct of the research project that do not have a major impact on the participant's rights, safety, or well-being, or on the completeness, accuracy, and reliability of the research project data are considered minor protocol deviations. Minor protocol deviations are reported to the IRB by the Investigator at the time of Continuing Review. 1.1.3 Major Protocol Deviation: Examples of major protocol deviations are described below. There may be other examples. Investigators are encouraged to contact the IRB to determine on a case-by-case basis whether a protocol violation Version No. 10 Page 1 of 8

has occurred. Major protocol deviations falling into the following categories shall be considered an Unanticipated Problem that will require IRB review as determined by the IRB Chair, IRB designee or Board: I. The deviation has harmed or posed a significant or substantive risk of harm to a research participant(this is also an unanticipated problem) Examples: A research participant received the wrong treatment or incorrect dose. A research participant met withdrawal criteria during the research project but was not withdrawn. A research participant received an excluded concomitant medication. II. The deviation compromises the scientific integrity of the data collected for the research project. Examples: A research participant was enrolled but does not meet the protocol's eligibility criteria. Failure to treat research participants per protocol procedures that specifically relate to primary efficacy outcomes (if it involves patient safety, it meets the first category above). Changing the protocol without prior IRB approval (except where necessary to eliminate an apparent immediate hazard to the participant). Inadvertent loss of samples or data. III. The deviation is a willful or knowing breach of human subjects research protection regulations, policies, or procedures on the part of the investigator(s). Examples: Failure to obtain informed consent prior to initiation of research projectrelated procedures. Falsifying research or medical records. Performing tests or procedures beyond the individual's professional scope or privilege status (credentialing). IV. The deviation involves a serious or continuing noncompliance with federal, state, local, or University human subjects research protection regulations, policies, or procedures. Examples: Working under an expired professional license or certification. Failure to follow federal and/or local regulations and intramural research or University policies. Repeated minor deviations. V. The deviation is inconsistent with the HRPP s research, medical, or ethical principles. Version No. 10 Page 2 of 8

Examples: A breach of confidentiality. Inadequate or improper informed consent procedure. 1.2 Review of Protocol Deviations If, in the opinion of the Investigator, the deviation represents a minor protocol deviation, the investigator will track this deviation in the Protocol Deviation Summary Report and submit this at the time of Continuing Review. If, in the opinion of the Investigator, the deviation represents a major protocol deviation or meets the criteria for an unanticipated problem involving risks to participants or others, the investigator shall complete the Protocol Deviation Report and submit this to the IRB within five (5) University business days. The investigator will also track this deviation in the Protocol Deviation Summary Report and submit this at the time of Continuing Review. Whether the Protocol Deviation Report or the Protocol Deviation Summary Report is submitted, the IRB Chair or IRB designee shall also determine whether any of the protocol deviations meet the definition of an unanticipated problem involving risks to participants or others. If the IRB Chair or IRB designee determines that the deviation may represent an unanticipated problem involving risks to participants or others or that the deviation resulted from serious or continuing noncompliance, the IRB Administrator shall place the deviation report on the agenda of the next available IRB meeting for review. If the IRB Chair or IRB designee determines that the deviation is NOT an unanticipated problem involving risks to participants or others, the IRB Chair or IRB designee shall note this determination in the IRB s electronic information system. The investigator must log this event in the Protocol Deviation Summary Report and submit this report at the time of Continuing Review. 1.3 Unanticipated Problems Involving Risks to Participants or Others An unanticipated problem is any incident, experience, or outcome that meets all three of the following criteria: (1) is unanticipated or unexpected; (2) is related or possibly related to the research; and (3) places participants or others at greater risk of harm than previously known or recognized. Investigators are required to submit to the IRB within five (5) University business days of discovery any unanticipated problems (both internal and external) involving risks to participants or others. This is accomplished by answering the questions within the Unanticipated Problem Report form. If all three criteria are answered YES, the event may constitute an unanticipated problem; however, only the convened IRB can make this determination. To receive the IRB determination, the investigator must submit the Unanticipated Problem form to the IRB for further review. Version No. 10 Page 3 of 8

If any of the three criteria in the form are not answered YES, the investigator should log this event in the Summary of Participant Harms and submit the Summary of Participant Harms to the IRB at Continuing Review. There is a high probability that the following problems/events represent some of the types of unanticipated problems involving risks to participants or others: Any harm experienced by a participant that in the opinion of the Investigator, is both unexpected and related to the research, regardless of whether the harm was an on-site or off-site adverse event and regardless of whether the harm was a serious or non-serious adverse event. Information that indicates a change to the risks or potential benefits of the research. For example: An interim analysis or safety monitoring report indicates that frequency or magnitude of harms or benefits may be different from that initially presented to the IRB. A paper is published from another study that shows that the risks or potential benefits of the research may be different from that initially presented to the IRB. A breach of confidentiality of the research project data than was previously known or recognized. A change to the protocol made without prior IRB review to eliminate an apparent immediate hazard to a research participant. Incarceration of a participant who is enrolled in a protocol not approved to enroll prisoners. A sponsor-imposed study suspension due to risk to participants. A complaint by a participant when the complaint indicates unexpected risks or when it cannot be resolved by the research team. A change in FDA labeling or FDA withdrawal from marketing of a drug, device, or biologic used in the research protocol. An unanticipated adverse device effect (any serious adverse effect on health or safety or any life-threatening problem or death caused by, or associated with, a device, if that effect, problem, or death was not previously identified in nature, severity, or degree of incidence in the investigational plan or application [including a supplementary plan or application], or any other unanticipated serious problem associated with a device that relates to the rights and welfare of participants). It is within the authority of the IRB to initiate a For-Cause Evaluation or to require IRB Education or QI/Evaluation visits to promote research integrity if the IRB receives an excessive number of reported protocol deviations or unanticipated problems involving Version No. 10 Page 4 of 8

risks to participants or others or if the IRB independently suspects investigator noncompliance or improprieties on the part of the investigator and/or research personnel. 1.4 Determination of an Unanticipated Problem Involving Risks to Participants or Others If the IRB Chair or IRB designee determines on the Unanticipated Problem Report form that the problem/event may represent an unanticipated problem involving risks to participants or others or the problem/event resulted from serious or continuing noncompliance, the IRB Administrator shall place the event on the agenda of the next available IRB meeting for review. If the IRB Chair or IRB designee determines on the Unanticipated Problem Report form the problem/event is NOT an unanticipated problem involving risks to participants or others and did not result from serious or continuing noncompliance, the IRB will administratively withdraw the submission and will request the Investigator log this event in the Summary of Participant Harms and submit it to the IRB at Continuing Review. 1.5 Review of an Unanticipated Problem Involving Risks to Participants or Others by the Convened IRB In reviewing events that may represent unanticipated problems, the convened IRB shall use the primary and secondary reviewer system, as described in SOP 403, Initial Review - Criteria for IRB Approval. The Unanticipated Problem Report form will be provided to all Board members, per SOP 302: Administrative Review and Distribution of Materials. The IRB submission materials will be available at the Board meeting for review. The possible actions that could be taken by the IRB at the meeting include, but are not limited to: Requiring the investigator to modify the protocol. Modifying the information disclosed during the consent process. Providing additional information to past participants. Notifying current participants when such information might relate to participants willingness to continue to take part in the research. Requiring that the current participants re-consent to participation. Modifying the continuing review schedule. Monitoring the research. Monitoring the consent process and documentation. Suspending the research. Terminating the research. Referring to other organizational entities (e.g., VA Research and Development Committee, Radiation Safety Committee). Obtaining additional information. The IRB shall report Unanticipated Problems in accordance with SOP 308: Reporting to Regulatory Agencies and Institutional Officials. Version No. 10 Page 5 of 8

Following the convened IRB review of the unanticipated problem, more than minor modifications to the approved protocol or research documentation shall be submitted by the Investigator as described in SOP 405: Modification for review by the convened IRB. During QI/Evaluation or Continuing Review, the IRB staff or IRB reviewer may have questions about unanticipated problems involving risks to participants or others that were not submitted to the IRB. These shall be submitted to the IRB by the Investigator. In this case, if the IRB agrees, the IRB may determine an Unanticipated Problem occurred even though the investigator did not submit the form for determination. The unfounded classification of a Serious Adverse Event constitutes serious non-compliance 1.6 Unanticipated Problems Involving Risks to Participants or Others and Unanticipated Serious Adverse Events in VA Research Projects For reporting, review, and determination of unanticipated problems involving risks to participants or others and unanticipated serious adverse events in VA research projects involving serious unanticipated adverse, see SOP 603A: Veterans Affairs Medical Center. 2. SCOPE This SOP applies to all research submitted to the IRB. 3. RESPONSIBILITY It is the responsibility of the HRPP Director and IRB Chair to review all events submitted as unanticipated problems involving risks to participants or others to determine if the event should be reported in accordance with SOP 308: Reporting to Regulatory Agencies and Institutional Officials. The IRB Chairs are responsible to review reports of unanticipated problems involving risks to participants and others and protocol deviations and forward them to the convened IRB when appropriate. The IRB Chair or IRB designee is responsible for selecting one Primary and one Secondary reviewer with the relevant expertise to review protocol deviations and/or unanticipated problems. If the IRB Chair or IRB designee cannot select Primary and Secondary reviewers with the relevant expertise, the IRB Chair or IRB designee shall defer the review to another IRB with Primary and Secondary reviewers with the relevant expertise or obtain consultation to obtain that expertise. Version No. 10 Page 6 of 8

Investigators involved in human participant research shall report all protocol deviations, per Section 1.1 of this policy. Investigators involved in human participant research shall report all suspected unanticipated problems involving risks to participants or others to the IRB, per Section 1.3 of this policy. 4. APPLICABLE REGULATIONS AND GUIDELINES 45 CFR 46.103,109 21 CFR 56.108,109 OHRP Guidance on Reviewing and Reporting Unanticipated Problems Involving Risks to Subjects and Others and Adverse Events (Jan. 2007) 5. REFERENCES TO OTHER APPLICABLE SOPS SOP 301: Research Submission Requirements SOP 302: Administrative Review and Distribution of Materials SOP 308: Reporting to Regulatory Agencies and Institutional Officials SOP 403: Initial Review Criteria for IRB Approval SOP 405: Modifications SOP 603D: Communication with Research Participants SOP 901: Quality Improvement Program SOP 903: Noncompliance/Scholarly Misconduct 6. ATTACHMENTS 407-A Unanticipated Problem Report 407-B Protocol Deviation/Violation Report 407-C Summary of Participant Harms 407-D Protocol Deviation Summary Report 7. PROCESS OVERVIEW The IRB Staff confirms that all documents are reviewed for submission per SOP 301: Research Submission Requirements. 7.1 Review Procedures for Protocol Deviations If the IRB Chair or IRB designee determines and documents on the Protocol Deviation Report form that the deviation is NOT an unanticipated problem involving risks to participants or others and the deviation was not a result of serious or continuing noncompliance, the IRB Chair or IRB designee shall withdraw the event in the IRB s electronic information system. If the IRB Chair or IRB designee determines and documents on the Protocol Deviation Report form that the deviation may represent an unanticipated problem involving risks to participants or others or that the deviation resulted from serious or continuing noncompliance, the IRB Administrator shall place the deviation report on the agenda of the next available IRB meeting for review. The IRB Reviewer will present the protocol deviation to the convened IRB for discussion and possible action(s). See Section 1.5 of this policy for possible actions. Version No. 10 Page 7 of 8

Following review, the IRB Administrator will update the IRB s electronic information system and notifies the investigator of the IRB s action. 7.2 Review Procedures for Unanticipated Problems Involving Risks to Participants or Others: If the IRB Chair or IRB designee determines and documents on the Unanticipated Problems Report form that the event is NOT an unanticipated problem involving risks to participants or others and the event is not a result of serious or continuing noncompliance, the IRB Chair or IRB designee shall indicate withdrawal of the event and request the Investigator log this event in the Summary of Participant Harms which shall be submitted by the Investigator at Continuing Review. The IRB Administrator will update the IRB s electronic submission system and sends a withdrawal letter to the investigator If the IRB Chair or IRB designee determines and documents on the Unanticipated Problem Report Form that the problem/event may represent an unanticipated problem involving risks to participants or others or the problem/event resulted from serious or continuing noncompliance, the IRB Administrator will place the event on the agenda of the next available convened IRB meeting for review. The IRB Reviewer will present the unanticipated problem to the convened IRB for discussion and IRB action(s). See Section 1.3 of this policy for possible actions. Following review, the IRB Administrator will update the IRB s electronic information system and notify the investigator of the IRB s action. 7.3 Reporting Requirements for Unanticipated Problems Involving Risks to Participants or Others, and Protocol Deviations If the convened IRB determines that an event is an unanticipated problem involving risks to participants or others, the IRB staff will forward a copy of the report and the IRB letter to the Director of HRPP for reporting to regulatory agencies and Institutional Officials per SOP 308: Reporting to Regulatory Agencies and Institutional Officials. APPROVED BY: DATE: 09/09/2016 NEXT ESTABLISHED REVIEW DATE: AUGUST 2018 Version No. 10 Page 8 of 8